Everolimus in Treating Patients With Stage IV Melanoma
This study has been completed.
North Central Cancer Treatment Group
Information provided by:
National Cancer Institute (NCI)
First received: December 7, 2004
Last updated: June 17, 2012
Last verified: January 2007
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Primary Completion Date:||July 2007 (Final data collection date for primary outcome measure)|
Rao RD, Allred JB, Windschitl HE, et al.: N0377: results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma. [Abstract] J Clin Oncol 25 (Suppl 18): A-8530, 479s, 2007.
Rao RD, Windschitl HE, Allred JB, et al.: Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma. [Abstract] J Clin Oncol 24 (Suppl 18): A-8043, 463s, 2006.